Humacyte’s Symvess offers a novel solution for patients with severe vascular injuries, marking a significant advancement in trauma …
Humacyte’s Symvess offers a novel solution for patients with severe vascular injuries, marking a significant advancement in trauma …
On December 19, the clinical research world turns its attention to psychedelic medicine, with new data, global trial …
December 18 brings a milestone for cell therapy in graft-versus-host disease—and a setback for Duchenne muscular dystrophy research, …
With generative AI powering personalized insights, Dexcom’s new Stelo CGM enters the market as the first FDA-cleared over-the-counter …
With its first-in-class mechanism and monthly dosing, Depemokimab sets a new benchmark in biologic treatment for high-burden asthma …
Regulatory approval marks a pivotal moment for psychedelic medicine, as COMPASS Pathways prepares to test psilocybin in treatment-resistant …
The bispecific antibody earns full approval after demonstrating durable responses in heavily pre-treated patients.
Arvinas and Pfizer’s vepdegestrant becomes the first oral PROTAC therapy approved for ER-positive breast cancer, opening new avenues …
On November 14, 2024, PDS Biotech announced significant updates to its Phase 3 clinical trial design for its …
On November 13, 2024, the U.S. Food and Drug Administration (FDA) approved a novel gene therapy for aromatic …
Already a subscriber? Log in